FDA to decide on Pfizer's COVID-19 vaccine EUA by end of January

The FDA will decide on Pfizer's emergency use authorization (EUA) for its COVID-19 vaccine before the end of January.

FDA Director General Eric Domingo said the evaluation, which usually takes three to six months, is being expedited due to the pandemic and an executive order allowing EUA issuance.

Pfizer submitted its application on December 23, and it has been distributed to reviewers for a two-week evaluation focusing on regulatory quality and clinical trial efficacy and safety.